DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 146 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $321,053 | -9.6% | 25,240 | +0.0% | 0.00% | -33.3% |
| Q2 2023 | $355,323 | +93160.6% | 25,236 | +2.3% | 0.00% | 0.0% |
| Q1 2023 | $381 | -12.0% | 24,670 | -6.6% | 0.00% | 0.0% |
| Q4 2022 | $433 | -99.9% | 26,418 | 0.0% | 0.00% | -25.0% |
| Q3 2022 | $479,000 | +38.0% | 26,418 | +0.1% | 0.00% | +33.3% |
| Q2 2022 | $347,000 | +41.6% | 26,380 | 0.0% | 0.00% | +50.0% |
| Q1 2022 | $245,000 | -8.2% | 26,380 | -16.8% | 0.00% | 0.0% |
| Q4 2021 | $267,000 | +394.4% | 31,692 | +1905.8% | 0.00% | – |
| Q3 2021 | $54,000 | -6.9% | 1,580 | 0.0% | 0.00% | – |
| Q2 2021 | $58,000 | -20.5% | 1,580 | -3.1% | 0.00% | – |
| Q1 2021 | $73,000 | -21.5% | 1,630 | 0.0% | 0.00% | -100.0% |
| Q4 2020 | $93,000 | +19.2% | 1,630 | +6.5% | 0.00% | 0.0% |
| Q3 2020 | $78,000 | +239.1% | 1,530 | +302.6% | 0.00% | – |
| Q2 2020 | $23,000 | – | 380 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $72,236,000 | 20.73% |
| SV Health Investors, LLC | 449,951 | $26,871,000 | 18.64% |
| Redmile Group, LLC | 4,978,941 | $297,342,000 | 5.49% |
| Sunesis Advisors, LLC | 96,299 | $5,751,000 | 5.29% |
| Eversept Partners, LP | 418,652 | $25,001,897 | 3.43% |
| Opaleye Management Inc. | 222,000 | $13,081,000 | 2.64% |
| Avoro Capital Advisors LLC | 1,860,000 | $111,079,000 | 2.20% |
| SPHERA FUNDS MANAGEMENT LTD. | 282,965 | $16,899,000 | 1.59% |
| SECTORAL ASSET MANAGEMENT INC | 224,359 | $13,399,000 | 1.23% |
| Artal Group S.A. | 650,000 | $38,818,000 | 1.09% |